compass

Our Vision

Changing the face of cancer one patient at a time by enhancing the visualization and precision of cancer surgery, giving patients a chance at a longer and better quality of life.

Contact Us

About Us

NX Development Corp. (NXDC) is a life sciences company based in Lexington, KY dedicated to the development of ALA HCl for tumor visualization.

NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG in Pinneberg, Germany (PHN).  The companies share an eight-year working relationship and are wholly-owned by SBI Holdings Inc. in Tokyo, Japan.

Executive Team

Sal DeSena

Salvatore DeSena, MD, MBA

Chief Executive Officer

Salvatore DeSena MD MBA is an experienced physician executive with comprehensive knowledge of medical affairs operations throughout the medical imaging industry. He has held senior Medical Affairs leadership roles for global life sciences companies and was part of a team that successfully submitted a new diagnostic imaging contrast agent for approval by the FDA. In addition, he is involved with angel and venture capital investing groups, consults for multiple expert networks, and serves as an advisor to several health care startups. As an Attending Radiologist, Dr. DeSena’s entrepreneurial interest led him to plan, develop and operate a multi-modality outpatient imaging facility. He later founded a niche teleradiology service which has provided on-site and remote radiology image interpretation and consultation services for over 15 years.


Dr. DeSena holds a BS in Electrical Engineering from Polytechnic University, an MS in Engineering Economic-Systems from Stanford University, an MD with distinction in research from SUNY-Downstate Medical Center, and a Global Executive MBA with certification in Health Sector Management from Duke University Fuqua School of Business. His medical training includes a fellowship in Body MRI at Johns Hopkins Hospital and a Diagnostic Radiology Residency at Robert Wood Johnson Hospital. His combination of business, engineering and medical experience allow him to provide a wide range of value to life science companies.